---
title: "Inventiva SA (IVA) stock listing, news and investor profile"
url: "https://aibio.space/companies/inventiva/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Inventiva SA (EURONEXT: IVA), France. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space."
---

IVA Inventiva SA EURONEXT · France

# Inventiva SA (IVA) news

Financings · 2026-07-29

## [Inventiva says cash covers operations to end of Q2 2027 after June financings](https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/)

Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.

## Latest Inventiva SA news

We have not published a story on Inventiva SA yet. When there is news, it will appear here.

## Inventiva SA at a glance

- **Ticker**: IVA

- **Listing**: EURONEXT

- **Country**: France

- **Cash, Jun 30, 2025**: €122.1 million

### Related companies

- [Aelis Farma SA](https://aibio.space/companies/aelis-farma/) EURONEXT: AELIS
- [genOway SA](https://aibio.space/companies/genoway/) EURONEXT: ALGEN
- [Valneva](https://aibio.space/companies/valneva/) EURONEXT: VLA
- [Euroapi SA](https://aibio.space/companies/euroapi/) EURONEXT: EAPI
- [NFL Biosciences SA](https://aibio.space/companies/nfl-biosciences/) EURONEXT: ALNFL
- [Valbiotis SA](https://aibio.space/companies/valbiotis/) EURONEXT: ALVAL
- [Genfit SA](https://aibio.space/companies/genfit/) EURONEXT: GNFT
- [Afyren SA](https://aibio.space/companies/afyren/) EURONEXT: ALAFY

### Also on EURONEXT

- [Hyloris Pharmaceuticals SA](https://aibio.space/companies/hyloris-pharmaceuticals/) HYL
- [Genfit SA](https://aibio.space/companies/genfit/) GNFT
- [Abivax SA](https://aibio.space/companies/abivax/) ABVX
- [MedinCell SA](https://aibio.space/companies/medincell/) MEDCL
- [bonyf NV](https://aibio.space/companies/bonyf/) MLBON
- [AB Science SA](https://aibio.space/companies/science/) AB

## What Inventiva SA does

Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis, or MASH. It has a wholly-owned research and development facility and expertise in compounds that target nuclear receptors, transcription factors and epigenetic modulation. In February 2025 the company decided to focus exclusively on lanifibranor, and it discontinued research on its other pre-clinical programs, including YAP-TEAD and NR4A1, since June 2025. Lanifibranor is an orally available small molecule that activates all three peroxisome proliferator-activated receptor isoforms, which the company says can produce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects. The NATIVE Phase 2b trial met its primary endpoint at a dose of 1,200 mg after 24 weeks, and the FDA granted lanifibranor Breakthrough Therapy Designation for MASH in October 2020. The Phase 3 NATiV3 trial began in September 2021, with topline results targeted for the fourth quarter of 2026. If the results are positive, the company targets a new drug application in the first half of 2027, with potential commercialization in 2028. The company describes MASH as a progressive, chronic liver disease that affects 2-6% of the United States adult population.

| Product or program | What it is | Stage |
|---|---|---|
| Lanifibranor | Oral small molecule for MASH, the company's only product candidate in development | Phase 3 NATiV3 trial; topline results targeted for the fourth quarter of 2026 |

Summarised from the company's [20-F filed Apr 8, 2026](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm).

## Inventiva SA annual financials

| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | [€9.2 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) | [€17.5 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) |
| Research and development | [€90.9 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) | [€110.0 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) |
| Cash from operations | [-€85.9 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) | [-€81.6 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925035122/) |
| Cash and equivalents | [€96.6 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925094101/) | [€26.9 million](https://www.sec.gov/Archives/edgar/data/1756594/000110465925094101/) |

Latest balance sheet, Jun 30, 2025 (6-K): cash and equivalents €122.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Inventiva SA

What is the ticker symbol of Inventiva SA?

Inventiva SA trades under the ticker IVA on EURONEXT.

Where is Inventiva SA listed?

Inventiva SA is listed on EURONEXT. Our directory also records these other listings: DUS:6IV; FWB:6IV; GETTEX:6IV; HAM:6IV; HAN:6IV; LS:A2DLV9; LSE:0RNK; LSX:A2DLV9; MUN:6IV; NASDAQ:IVA; OTC:IVEVF; SWB:6IV; TRADEGATE:6IV; XETR:6IV.

What is the SEC CIK of Inventiva SA?

The SEC Central Index Key (CIK) for Inventiva SA is 1756594. Its filings are on SEC EDGAR.

How many shares does Inventiva SA have outstanding?

193,236,978 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-08.

Which country or territory is Inventiva SA listed under?

Our directory records Inventiva SA under France.

What does Inventiva SA do?

Our directory classifies Inventiva SA as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Inventiva SA?

The ISIN recorded for Inventiva SA is FR0013233012.

Does aibio.space cover Inventiva SA?

aibio.space lists Inventiva SA among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Inventiva SA incorporated?

SEC records list its state or country of incorporation as I0.

What does Inventiva SA develop?

Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis, or MASH. It has a wholly-owned research and development facility and expertise in compounds that target nuclear receptors, transcription factors and epigenetic modulation.

What is Lanifibranor from Inventiva SA?

Lanifibranor: Oral small molecule for MASH, the company's only product candidate in development Stage: Phase 3 NATiV3 trial; topline results targeted for the fourth quarter of 2026.

What is the latest Inventiva SA (IVA) stock news?

Our latest story on Inventiva SA, dated Jul 29, 2026: "Inventiva says cash covers operations to end of Q2 2027 after June financings". Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months. [Source](https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/).

What is Inventiva SA's latest stock offering or financing news?

Our latest financing story, dated Jul 29, 2026: "Inventiva says cash covers operations to end of Q2 2027 after June financings". Inventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months. [Source](https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/).

How long will Inventiva SA's cash last?

From our story of Jul 29, 2026: It says that without additional capital the company may be required to curtail, delay or discontinue programs, and that it may be unable to continue as a going concern. [Source](https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/).

Is Inventiva SA a smaller reporting company?

SEC records list Inventiva SA's filer category as: Accelerated filer.

## Investor discussion: Inventiva SA

Members talk about Inventiva SA (IVA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Inventiva SA, newest first. Each line links the filing it comes from.

1. 2026-07-29 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184326005018/exh_991.htm)
2. 2026-06-02 Financings Reported a financing. SEC Form F-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465926069136/tm2615682-1_f3asr.htm)
3. 2026-05-22 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465926065699/tm2615376d1_ex99-1.htm)
4. 2026-03-30 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184326002025/exh_991.htm)
5. 2026-02-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184326000836/exh_991.htm)
6. 2025-11-24 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325007502/exh_991.htm)
7. 2025-11-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465925110422/tm2528355-4_424b5.htm)
8. 2025-10-14 Financings Reported a financing. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465925099260/tm2528355-1_f3.htm)
9. 2025-07-29 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325004785/exh_991.htm)
10. 2025-07-07 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325004339/exh_991.htm)
11. 2025-05-23 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325003416/exh_991.htm)
12. 2025-05-02 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465925044103/tm2513664d1_ex99-1.htm)
13. 2025-04-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465925034195/tm2511984d1_ex99-1.htm)
14. 2025-03-26 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325001725/exh_991.htm)
15. 2025-02-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000117184325000721/exh_991.htm)
16. 2024-12-16 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1756594/000110465924128902/tm2431159d1_ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:IVA on TradingView](https://www.tradingview.com/symbols/EURONEXT-IVA/).

## SEC filings and registration

- **SEC name**: Inventiva S.A.

- **CIK**: 1756594

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: IVA (Nasdaq), IVEVF (OTC)

- **State or country of incorporation**: I0

- **Fiscal year ends**: December 31

- **Filer category**: Accelerated filer

- **Business address**: 50 RUE DE DIJON, DAIX, France, 21121

- **Phone**: 33380447500

- **Shares outstanding**: 193,236,978 as of 2025-12-31 (20-F filed 2026-04-08)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326006471/f6k_100626.htm) filed 2026-10-06
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000110465926111143/iva-20260630x6k.htm) filed 2026-09-28
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326005860/f6k_090226.htm) filed 2026-09-03
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326005810/f6k_083126.htm) filed 2026-09-01
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326005018/f6k_072926.htm) filed 2026-07-29
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326004554/f6k_070926.htm) filed 2026-07-09
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000117184326004459/f6k_070226.htm) filed 2026-07-06
- [6-K](https://www.sec.gov/Archives/edgar/data/1756594/000110465926073545/tm2617723d2_6k.htm) filed 2026-06-12

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001756594), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Inventiva SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker IVA, recorded under France. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Inventiva SA

- **Ticker**: IVA

- **Listing**: EURONEXT

- **Country or territory**: France

- **Business scope**: Biotechnology

- **ISIN**: FR0013233012

- **Other listed symbols**: DUS:6IV; FWB:6IV; GETTEX:6IV; HAM:6IV; HAN:6IV; LS:A2DLV9; LSE:0RNK; LSX:A2DLV9; MUN:6IV; NASDAQ:IVA; OTC:IVEVF; SWB:6IV; TRADEGATE:6IV; XETR:6IV

- **Last quote in directory**: 2026-10-22

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-IVA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/inventiva/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Inventiva SA (IVA) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/inventiva/